

### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

## (19) World Intellectual Property Organization International Bureau

# PO POPE

### 1 MATAR BINGNYA NI MANDA NAKA BANTA BANTA BANTA KANTA BINGA BANTA BANTA BANTA BANTA BANTA BANTA BANTA MANDA MAN

### (43) International Publication Date 3 June 2004 (03.06.2004)

### **PCT**

### (10) International Publication Number WO 2004/045563 A2

(51) International Patent Classification<sup>7</sup>: A61K

(21) International Application Number:

PCT/US2003/037653

(22) International Filing Date:

18 November 2003 (18.11.2003)

(25) Filing Language:

**English** 

(26) Publication Language:

English

(30) Priority Data: 10/298,377

18 November 2002 (18.11.2002) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US Filed on 10/298,377 (CIP) 18 November 2002 (18.11.2002)


(71) Applicant (for all designated States except US): THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): CHERESH, David, A. [US/US]; 3277 Lone HIII Lane, Encinitas, CA 92024 (US). PAUL, Robert [DE/DE]; Bruderhofstr.9, 81371 Munich (DE). ELICEIRI, Brian [US/US]; 3104 Hataca Road, Carlsbad, CA 92009 (US).
- (74) Agents: CEPURITIS, Talivaldis et al.; Olson & Hierl, Ltd., 20 North Wacker Drive, 36th Floor, Chicago, IL 60606 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

### (54) Title: METHOD OF TREATMENT OF MYOCARDIAL INFARCTION



and only one has been the risk and the cost and the tip one of the one and the same
APP CBF que mie man che Péticambitre Colleccobé gyrostyggo 1333 The Bis Six bes blue Ses 632
rightypero typolotigue oprinstero acceptante etgalendre seconomic 1575
typectypgs conseque typecycle tentectypy consequely meanines 1677
proceeptoto testegennu ekstytopur settropher constiguing parapayong 1693
ASSCRIBATION CORRECTIONS STREET-SCHOOL COCKINGING PRINTINGS TRANSPORTED 1753
ACCEPTATED TEACHETERS ARE ARREST OF THE PROPERTY AND ARREST AND ARREST AREA
Abstractor ter-record abstractors sensitudes grantiques stittaness 1073
anglasment ett. Litte de autorigen entre représent mesons par montre la la la la comme de
taugurene toprecore destituer stimuffite etaugherne apteixenter 1283
who powerfy etchargest proceduling communities alphysicism processes to
tukongago tigganting ipigooping mesasyons acarpeany impession \$115
beginshess management suppressed commercial descriptions concepts \$173
7622 0004 0004 0004

 (57) Abstract: Myocardial infarction in a mammal is treated by administering to the mammal a therapeutically effective amount of a chemical Src family tyrosine kinase protein inhibitor and the use of such inhibitor compounds for the preparation of a medicament for treating myocardial infarction. Myocardial infarction can be prevented by administering to the mammal a prophylactic amount of the inhibitor. The inhibitor preferably is an inhibitor of Src protein selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof. The Src family tyrosine kinase inhibitors can be used to prepare medicaments for the treatment of myocardial Also disclosed are infarction. articles of manufacture containing a chemical Src family tyrosine kinase inhibitor.

### WO 2004/045563 A2



<sup>c</sup> Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

#### Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.